Company record · CLDX · In Vitro & In Vivo Diagnostic Substances
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. disclosed a change in its chief financial officer, effective March 31, 2027. Until then the filing lists Sam Martin in the role. See the filing record.
The record holds 1 verified CFO change for Celldex Therapeutics, Inc. from Form 8-K filings, filed July 15, 2026 and the CFO signature on its 10-K filed February 25, 2026.
The CFO seat
Computed from the records below: a move filed on or after the 10-K replaces the 10-K's signature.
| Status | Change pending |
|---|---|
| Officer | Sam Martin |
| Effective | March 31, 2027 |
| Basis | Latest move: departure, 8-K filed July 15, 2026 |
Seat timeline
2Every verified record for this seat, newest first, dated as the filing states it.
2026-07-15Departure
Celldex Therapeutics, Inc. discloses CFO departure: Sam Martineffective March 31, 2027 · 8-K filed July 15, 2026 · sec.gov, Item 5.02
2026-02-2510-K signature
Sam Martin signed the annual report as Senior Vice President, Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer)
10-K filed February 25, 2026 · sec.gov
“/s/ SAM MARTIN Senior Vice President, February 25, 2026 Sam Martin Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer)”
Company
| Ticker | CLDX |
|---|---|
| SEC CIK | 0000744218 |
| Industry (SIC) | In Vitro & In Vivo Diagnostic Substances (2835) |
| Roster note | The DEF 14A filed 2026-04-29 also names Sam Martin alongside a Chief Financial Officer title. An 8-K with Item 5.02 was filed on 2026-07-15, after this 10-K; any CFO change it reports is tracked on the moves record. |
Same industry on the record
2Other companies the roster files under SIC “In Vitro & In Vivo Diagnostic Substances”.
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.